Journals / Selçuk Tıp Dergisi / 2002 / Cilt: 18 - Sayı: 1

A retrospective follow-up study on the patients with the immune thrombocytopenic purpura

Kliniğimizde takip edilen "İmmun trombositopenik purpura" olgularının retrospektif incelenmesi

Pages
27–32
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Patients with ITP should be monitored closely because of the bleeding risk and should be detected seriously because of an underlying disease risk and should be alert against the malignity or autoimmune disease at the chronic stage or atter the remission phase.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Idiopathic thrombocytopenic purpura (ITP) is the most common seen acquired bleeding disorder of childhood. it has a benign course.
📊
Key Findings & Data:Nevertheless, it has a great importance because of an organ bleeding risk and possibility of an existance of underlying serious disease and chronicity. in our study we investigated retrospectively 86 patients diagnosed as ITP.
💡
Conclusion & Impact:Patients with ITP should be monitored closely because of the bleeding risk and should be detected seriously because of an underlying disease risk and should be alert against the malignity or autoimmune disease at the chronic stage or atter the remission phase.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Geriyedönük çalışma · Çocuk · İlaç tedavisi

Abstract

Idiopathic thrombocytopenic purpura (ITP) is the most common seen acquired bleeding disorder of childhood. it has a benign course. Nevertheless, it has a great importance because of an organ bleeding risk and possibility of an existance of underlying serious disease and chronicity. in our study we investigated retrospectively 86 patients diagnosed as ITP. Peak ages of the cases were 5 and 13 years. Except the intracranial bleeding, almost every type of bleeding were seen. We prefered corticosteroids for the first choice of treatment. 73 patients received high dose methylprednisolone for the treatment 41 of them (47.6%) recovered totally. Immediate increase in the thrombocyte count after the corticosteroid therapy was observed in 79% of the patients. Chronicity rate was as high as 41.8% and the ages of this group were similar to that of the peek incidence ages. None of the patients died. Four patients, resistant to medical treatment went to splenectomy. However, the increase of thrombocyte count was permanent in only one case. One of the patients diagnosed as ITP was accepted as systemic lupus erythematosus three months later and one as Hodgkin lymphoma three years later. Patients with ITP should be monitored closely because of the bleeding risk and should be detected seriously because of an underlying disease risk and should be alert against the malignity or autoimmune disease at the chronic stage or atter the remission phase.

Özet

İmmun trombositopenik purpura (İTP), çocukluk çağının en sık görülen akkiz kanama bozukluğu olup prognozu iyi olan bir hastalıktır. Buna rağmen, organ kanamaları riski, altta yatabilecek başka bir hastalığın varlığı ve kronikleşme eğilimi nedeniyle önemini korumaktadır. Çalışmamızda son dört yılda İTP tanısıyla takip ettiğimiz 86 hastayı retrospektif olarak inceledik. Olguların 5 ve 13 yaşlarında pik yaptığı, intrakraniyal kanama hariç hemen her tip kanama şekli varlığı görüldü. Başvuru esnasındaki trombosit sayıları çoğunluğunda (%60.4) 20000/mm_in altındaydı. Tedavide ilk tercihimiz kortikosteroidler oldu. 73 hastaya (%84.8) yüksek doz metilprednizolon tedavisi başlandı. Bunlardan 41'i (%47.6) tam olarak düzeldi. Kortikosteroide trombosit sayısının çabuk yükselmesi şeklinde yanıt ise %79 oranında başarı gösterdi. Kronikleşme.oranı %41.8 olarak saptandı. Kronikleşen olguların yaşları en sık görülen yaşlarla paralellik gösteriyordu. Hiç bir hastada ölüm olmadı. İlaca cevapsız dört hastada splenektomi yapıldı. Bunların yalnızca birinde trombosit yüksekliği kalıcı oldu. İTP tanısı koyduğumuz olguların biri üç ay sonra sistemik lupus eritematozus, biri de üç yıl sonra Hodgkin lenfoma tanısı aldı. İTP kanama riski nedeniyle yakından takip edilmeli, beraberinde bir hastalığın varlığı ihtimali nedeniyle iyice tetkik edilmeli ve kronik veya iyileşme sonrasındaki bir süreçte malign veya otoimmun bir fenomenin eklenebilme riski nedeniyle tetikte olunmalıdır.

🔖

Cite This Article

ÇALIŞKAN, Ü., DEMİRÖREN, K., DEMİRÖREN, S., ÖZEL, A. (2002). A retrospective follow-up study on the patients with the immune thrombocytopenic purpura. Selçuk Tıp Dergisi, Cilt: 18 - Sayı: 1, 27–32. https://ajindex.com/articles/319330

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (4)

  1. Imbach P. Idıopathic thrombocyîopenic purpura.ln: Lü-leyman JS, Hann İM, Blanchette VS, editors. Pediatric Hematology, Second Edition, Churchill Livingstone, London. 1999:437-53
  2. Breardsley DS, Nathan DG. Platelet abnormalitres in in-fancy and childhood. İn: Nathan DG, Orkin SH, editors. Nathan's and Oski's Hematology of Infancy and Child¬hood, 5th edition. WB Saunders Company, Phi-ladelphia. 1998(2):1590-1600
  3. Casella JF, Bovvers DC, Pelidis MA. Disorders of co-agulation. İn: Steuber CP, McMillan JA, DeAngelis CD, Feigin RD, Warshauw JB, editors. Oski's Pediatrics, third edition. üppincott Williams-Wilkins, Philadelphia. 1999:1477-81
  4. Montgomery RR, Scott JP. Idıopathic throm-bocytopenic purpura. İn: Behrman RE, Klİegman RM, Jenson HB. Nelson Textbook of Pediatrics, 16th edi¬tion. WB Saunders Company, Philadelphia 2000:1520¬2 5. Mehta YS, Pathare AV, Badakere SS, Ghosh K, Mo-hanty D. Influence of auto-antibody specificities on the clinical course in patients with chronic and acute İTP. Piatelets 2000;11(2): 94-8 6. Chong BH, Keng TB. Advances in the diagnosis of idi-opathic thrombocytopenic purpura. Semin Hematol 2000;37(3):249-60 7. Rand ML, Wright JF. Virus-associated idiopathic throm¬bocytopenic purpura. Transfus Sci 1998;19(3):253-9 8. Farrington P, Pugh S, Colville A, Flower A, Nash J, Morgan-Capner P, et al. A new method for active sur-veillance of adverse events from diphtheria/tetanus/ pertussis and measles/mumps/rubelia vaccines. Lan-cet 1995 4;345{8949):567-9 9. Neau D, Bonnet F, Michaud M, Perel Y, Longy-Boursier M, Ragnaud JM, Guiilard JM. Immune throm-bocytopenic purpura after recombinani hepatitis B vac-cine: retrospecttve study of seven cases. Scand J In-fect Dis 1998;30(2):115-8 10. Aster RH. Can drugs cause autoimmune throm-bocytopenic purpura? Semin Hematol 2000 Jul;37 (3):229-38 11. Ozsoylu S, İrken G, Karabent A. High-dose int-ravenous methylprednisolone for acute childhood idi¬opathic thrombocytopenic ourpura. Eur J Haematol 1989;42(5):431-5 12. Ozsoylu S, Sayii TR, Ozturk G. Oral megadose methy¬lprednisolone versus intravenous immunoglobulin for acute childhood idiopathic thrombocytopenic purpura. Pediatr Hematol Oncol 1993;10(4):317-21 13. Albayrak D, Islek I, Kalayci AG, Gurses N: Acute ım-mune thrombocytopenic purpura: a comparative study of very high oral doses of methylprednisolone and int-ravenousiy administered immune globulin. J Pediatr 1994,125:1004-7.